Six isostructural crystalline solvates of celecoxib are reported and the intermolecular interactions involving the solvent molecules are described.
Keywords: celecoxib, active pharmaceutical ingredient, API, solvate, crystal structure, isostructurality, disorder, PIXEL, anti-inflammatory
Abstract
Six isostructural crystalline solvates of the active pharmaceutical ingredient celecoxib {4-[5-(4-methylphenyl)-3-(trifluoromethyl)pyrazol-1-yl]benzenesulfonamide; C17H14F3N3O2S} are described, containing dimethylformamide (DMF, C3H7NO, 1), dimethylacetamide (DMA, C4H9NO, 2), N-methylpyrrolidin-2-one (NMP, C5H9NO, 3), tetramethylurea (TMU, C5H12N2O, 4), 1,3-dimethyl-3,4,5,6-tetrahydropyrimidin-2(1H)-one (DMPU, C6H12N2O, 5) or dimethyl sulfoxide (DMSO, C2H6OS, 6). The host celecoxib structure contains one-dimensional channel voids accommodating the solvent molecules, which accept hydrogen bonds from the NH2 groups of two celecoxib molecules. The solvent binding sites have local twofold rotation symmetry, which is consistent with the point symmetry of the solvent molecule in 4 and 5, but introduces orientational disorder for the solvent molecules in 1, 2, 3 and 6. Despite the isostructurality of 1–6, the unit-cell volume and solvent-accessible void space show significant variation. In particular, 4 and 5 show an enlarged and skewed unit cell, which can be attributed to a specific interaction between an N—CH3 group in the solvent molecule and the toluene group of celecoxib. Intermolecular interaction energies calculated using the PIXEL method show that the total interaction energy between the celecoxib and solvent molecules is broadly correlated with the molecular volume of the solvent, except in 6, where the increased polarity of the S=O bond leads to greater overall stabilization compared to the similarly-sized DMF molecule in 1. In the structures showing disorder, the most stable orientations of the solvent molecules make C—H⋯O contacts to the S=O groups of celecoxib.
Introduction
Understanding the structures and properties of crystalline solids can be of significant importance for active pharmaceutical ingredients (APIs) (Sun, 2009 ▸). Solid-form screening is an integral part of most pre-formulation activities (Morissette et al., 2004 ▸), with an aim to establish the range of solid forms that can exist for a given API. These generally include both polymorphs and multicomponent forms, which may variously be described as salts, cocrystals, solvates, etc. (Aitipamula et al., 2012 ▸).
The API of interest in this work is the anti-inflammatory drug celecoxib (see Scheme 1). To date, there is only one polymorph (Form III) of celecoxib for which a single-crystal X-ray structure has been reported (Dev et al., 1999 ▸; Wang et al., 2019 ▸) in the Cambridge Structural Database (CSD; Groom et al., 2016 ▸), although several polymorphs are established in the literature (Dev et al., 1999 ▸; Lu et al., 2006 ▸; Wang & Sun, 2019 ▸). Crystal structures are known for numerous multicomponent forms, including with pyrrolidin-2-one, caprolactam, valerolactam (Bolla et al., 2014 ▸), pyridin-2(1H)-one (Bolla & Nangia, 2019 ▸), nicotinamide (Zhang et al., 2017 ▸) and bis(proline) (as a zwitterion; Li et al., 2018 ▸). Some celecoxib cocrystals with 4,4′-bipyridine and 1,2-bis(pyridin-4-yl)ethylene have also been reported to form isostructural solvates (i.e. isostructural three-component crystals) when combined with acetone, THF or 1,4-dioxane (Wang et al., 2014 ▸).
We were initially interested in studying solvates of celecoxib as part of a broader structure–property correlation exercise to understand and address its pharmaceutical deficiencies, e.g. high punch sticking propensity (Wang et al., 2020 ▸; Paul et al., 2017 ▸, 2020 ▸), amorphous phase stability (Wang & Sun, 2019 ▸), poor flowability (Chen et al., 2020 ▸) and high elastic flexibility (Wang et al., 2019 ▸). In the course of this work, we identified a group of six solvates (see Scheme 1) that form an isostructural group, different from any of the multicomponent celecoxib crystal structures in the CSD. We describe the new structure type in this paper and explore aspects of the isostructurality, including variation of the unit-cell parameters, disorder of the solvent molecules, and the intermolecular interactions between the solvent and celecoxib molecules.
Experimental
Synthesis and crystallization
Single crystals suitable for X-ray analysis were obtained by slow cooling of a warm solution of celecoxib in either dimethylformamide (DMF, 1), dimethylacetamide (DMA, 2), N-methylpyrrolidin-2-one (NMP, 3), tetramethylurea (TMU, 4), 1,3-dimethyl-3,4,5,6-tetrahydropyrimidin-2(1H)-one (DMPU, 5) or dimethyl sulfoxide (DMSO, 6). The DMF (1) and DMA (2) solvates have been prepared previously (Chawla et al., 2003 ▸), but structural details were not provided. A powder X-ray diffraction pattern published by Chawla et al. (2003 ▸) clearly matches that simulated from the crystal structure of 2. The match to 1 is less clear, but additional thermal analysis is broadly consistent with our observations, so it seems probable that the structures described herein are consistent with the previously studied material.
Refinement of 1–6
H atoms bound to C atoms were placed in idealized positions and refined using a riding model, with U iso(H) = 1.2 or 1.5U eq(C). For the methyl group (C11) in celecoxib, the H atoms were allowed to rotate around the local threefold axis. H atoms of the NH2 groups were located in difference Fourier maps, then refined with isotropic displacement parameters, with the N—H and H⋯H distances restrained to 0.86 (1) and 1.50 (1) Å, respectively. All of the structures display rotational disorder of the CF3 group. This was modelled in each case as two sets of three F atoms, with site-occupancy factors constrained to sum to unity. To ensure a regular geometry, the C—F distances were restrained to a common refined value and the F⋯F distances were restrained to 1.633 times that value. All F atoms were refined with anisotropic ADPs. This produces highly distorted (prolate) ellipsoids in several cases, despite the inclusion of two sets of atomic sites, indicating that the rotational disorder is extensive. Given this rotational disorder, the distorted ellipsoids were considered to be an acceptable compromise to model the electron density in this region. For the disordered solvent molecules in 1, 2, 3 and 6, two sets of atoms were refined, with site-occupancy factors summing to unity, and with appropriate geometrical restraints. Anisotropic ADPs were applied to all non-H atoms and H atoms were placed in idealized positions and refined as riding. The structure and refinement details are presented in Table 1 ▸.
Table 1. Experimental details.
For all structures: monoclinic, P21/c, Z = 4. Experiments were carried out at 298 K with Cu Kα radiation using a Bruker D8-QUEST PHOTON-100 diffractometer. Absorption was corrected for by multi-scan methods (SADABS; Bruker, 2016 ▸). H atoms were treated by a mixture of independent and constrained refinement.
| 1 | 2 | 3 | |
|---|---|---|---|
| Crystal data | |||
| Chemical formula | C17H14F3N3O2S·C3H7NO | C17H14F3N3O2S·C4H9NO | C17H14F3N3O2S·C5H9NO |
| M r | 454.47 | 468.49 | 480.50 |
| a, b, c (Å) | 11.8973 (4), 8.8360 (3), 21.8286 (7) | 11.9584 (3), 9.2028 (2), 21.2811 (6) | 11.9978 (4), 9.0896 (3), 21.9732 (8) |
| β (°) | 103.4537 (13) | 103.3826 (12) | 101.358 (2) |
| V (Å3) | 2231.75 (13) | 2278.41 (10) | 2349.36 (14) |
| μ (mm−1) | 1.77 | 1.75 | 1.71 |
| Crystal size (mm) | 0.16 × 0.16 × 0.14 | 0.20 × 0.18 × 0.18 | 0.20 × 0.18 × 0.18 |
| Data collection | |||
| T min, T max | 0.440, 0.753 | 0.608, 0.753 | 0.593, 0.753 |
| No. of measured, independent and observed [I > 2σ(I)] reflections | 16627, 3940, 3362 | 38939, 4032, 3394 | 24378, 4146, 3112 |
| R int | 0.053 | 0.041 | 0.047 |
| (sin θ/λ)max (Å−1) | 0.596 | 0.597 | 0.596 |
| Refinement | |||
| R[F 2 > 2σ(F 2)], wR(F 2), S | 0.056, 0.149, 1.08 | 0.047, 0.129, 1.03 | 0.048, 0.136, 1.03 |
| No. of reflections | 3940 | 4032 | 4146 |
| No. of parameters | 346 | 345 | 389 |
| No. of restraints | 35 | 26 | 103 |
| Δρmax, Δρmin (e Å−3) | 0.25, −0.37 | 0.22, −0.29 | 0.22, −0.24 |
| 4 | 5 | 6 | |
|---|---|---|---|
| Crystal data | |||
| Chemical formula | C17H14F3N3O2S·C5H12N2O | C17H14F3N3O2S·C6H12N2O | C17H14F3N3O2S·C2H6OS |
| M r | 497.54 | 509.55 | 459.50 |
| a, b, c (Å) | 12.4050 (3), 8.9351 (2), 22.5727 (6) | 12.4495 (17), 8.7822 (13), 22.656 (3) | 11.9884 (3), 9.0230 (3), 20.8537 (6) |
| β (°) | 98.6702 (13) | 97.861 (5) | 100.3908 (9) |
| V (Å3) | 2473.36 (11) | 2453.9 (6) | 2218.78 (11) |
| μ (mm−1) | 1.66 | 1.68 | 2.63 |
| Crystal size (mm) | 0.16 × 0.14 × 0.14 | 0.20 × 0.20 × 0.18 | 0.14 × 0.12 × 0.12 |
| Data collection | |||
| T min, T max | 0.657, 0.753 | 0.526, 0.753 | 0.476, 0.753 |
| No. of measured, independent and observed [I > 2σ(I)] reflections | 27591, 4397, 3339 | 25201, 4318, 3733 | 22464, 3916, 3520 |
| R int | 0.034 | 0.031 | 0.042 |
| (sin θ/λ)max (Å−1) | 0.597 | 0.597 | 0.596 |
| Refinement | |||
| R[F 2 > 2σ(F 2)], wR(F 2), S | 0.046, 0.142, 1.04 | 0.040, 0.118, 1.02 | 0.044, 0.126, 1.04 |
| No. of reflections | 4397 | 4318 | 3916 |
| No. of parameters | 349 | 364 | 318 |
| No. of restraints | 15 | 29 | 15 |
| Δρmax, Δρmin (e Å−3) | 0.42, −0.20 | 0.25, −0.21 | 0.29, −0.28 |
Computational details
The crystal structures were energy-minimized with dispersion-corrected density functional theory (DFT-D) using the CASTEP module (Clark et al., 2005 ▸) in Materials Studio (Accelrys, 2011 ▸). The PBE functional (Perdew et al., 1996 ▸) was applied with a plane-wave cut-off energy of 520 eV, in combination with the Grimme semi-empirical dispersion correction (Grimme, 2006 ▸). The unit-cell parameters were constrained to the experimental values and the space group P21/c was imposed. Only one component of the rotationally-disordered CF3 group was included (arbitrarily). For the structures with disordered solvent molecules, separate models were minimized for each disorder component. In each case, minimization produced only small geometrical deviations from the starting structure, as expected for high-quality single-crystal structures (van de Streek & Neumann, 2010 ▸). The purpose of the optimization step is to place the structures on a common basis for comparison, particularly for the disordered structures, where the results of the crystallographic refinement are generally less precise. The DFT-D-optimized structures were then used as input for the PIXEL module of the CSP package (Gavezzotti, 2002 ▸, 2003 ▸, 2011 ▸). The calculated pairwise interaction energies are estimated to have an accuracy within a range of ca ±3 kJ mol−1.
Results and discussion
Description of the crystal structures
The molecular structures of 1–6 are shown in Figs. 1 ▸–6 ▸ ▸ ▸ ▸ ▸. In the crystal structures, the celecoxib molecules are arranged into pairs around inversion centres with two solvent molecules accepting N—H⋯O hydrogen bonds (Fig. 7 ▸). The local symmetry of this unit is effectively 2/m (C 2h), where the C=O (or S=O) group of each solvent molecule is approximately aligned along the local twofold rotation axis. For the TMU and DMPU molecules in 4 and 5, which themselves show twofold rotational point symmetry, this produces an ordered crystallographic result. The DMPU molecule displays minor conformational disorder of its six-membered ring (atoms C3S/C3SA in Fig. 5 ▸), but the parts of the molecule involved in binding to celecoxib are ordered and consistent for TMU and DMPU. For DMF (1), DMA (2), NMP (3) and DMSO (6), which do not possess twofold rotational symmetry, the crystal structure is disordered, with the molecules adopting two alternative orientations related by the local twofold axis. However, the full crystallographic environment of each solvent molecule is not twofold symmetric. Hence, the two orientations of the disordered solvent molecules have different total interaction energies (§3.3). With the solvent molecules removed from the structures, the void space between the celecoxib molecules defines one-dimensional (1D) channels along the b axis (Fig. 8 ▸). The solvent-accessible volume spans a considerable range for 1–6 (Table 2 ▸), constituting approximately 21–28% of the unit-cell volume.
Figure 1.
The molecular structure of 1, with displacement ellipsoids at the 50% probability level. H atoms have been omitted. The second disorder component of the DMF molecule [site-occupancy factor = 0.221 (7)] is shown in outline only. Atoms O1S and C3S are common to both DMF components.
Figure 2.
The molecular structure of 2, with displacement ellipsoids at the 50% probability level. H atoms have been omitted. The second disorder component of the DMA molecule [site-occupancy factor = 0.464 (8)] is shown in outline only. Atoms O1S, C2S, C3S and C4S are common to both DMA components.
Figure 3.
The molecular structure of 3, with displacement ellipsoids at the 50% probability level. H atoms have been omitted. The second disorder component of the NMP molecule [site-occupancy factor = 0.321 (8)] is shown in outline only. Atoms C2SA and C5SA are not labelled, C2SA is directly below C5S and C5SA is hidden behind C2S.
Figure 4.
The molecular structure of 4, with displacement ellipsoids at the 50% probability level. H atoms have been omitted. Disorder is not evident for the TMU molecule.
Figure 5.
The molecular structure of 5, with displacement ellipsoids at the 50% probability level. H atoms have been omitted. The alternative positions C3S and C3SA [site-occupancy factors = 0.584 (16):0.416 (16)] are shown for the DMPU molecule.
Figure 6.
The molecular structure of 6, with displacement ellipsoids at the 50% probability level. H atoms have been omitted. Atoms C1S and C2S are common to both disorder components for the DMSO molecule. The relatively large displacement ellipsoid of atom C2S was retained in preference to multiple atom sites for simplicity of the model.
Figure 7.
Hydrogen-bonded motif with two solvent molecules (TMU is shown) accepting N—H⋯O hydrogen bonds from two celecoxib molecules across a crystallographic inversion centre (indicated by the open circle). H atoms not involved in hydrogen bonding have been omitted. The atoms shown in ball-and-stick style conform to local 2/m (C 2h) point symmetry.
Figure 8.
Views of the 1D voids running along the b axis in the celecoxib framework structure, after removing the solvent molecules. Structure 6 is shown. The voids are generated using Mercury (contact surface, probe radius 1.2 Å; Macrae et al., 2020 ▸).
Table 2. Intermolecular interaction energies between the celecoxib and solvent molecules [E(tot)cel–solv] and between the solvent molecules [E(tot)solv–solv], calculated using the PIXEL method, together with the unit-cell volume (V cell), void volume (V void) and solvent molecular volume (V solv).
| Solvent | V cell (Å3) | V void (Å3)a | V solv (Å3)b | Disorder component | E(tot)cel–solv (kJ mol−1) | E(tot)solv–solv (kJ mol−1) | |
|---|---|---|---|---|---|---|---|
| 1 | DMF | 2231.8 | 485.4 (21.7%) | 76.7 | A | −144.0 | +3.8 |
| B | −132.2 | +5.1 | |||||
| 2 | DMA | 2278.4 | 481.8 (21.1%) | 93.2 | A | −160.5 | +2.4 |
| B | −162.1 | +3.3 | |||||
| 3 | NMP | 2349.4 | 617.5 (25.0%) | 100.1 | A | −170.7 | +1.9 |
| B | −160.1 | +1.5 | |||||
| 4 | TMU | 2473.4 | 572.3 (24.4%) | 121.8 | – | −155.1 | +0.7 |
| 5 | DMPU | 2453.9 | 692.1 (28.2%) | 127.9 | A | −180.5 | −1.9 |
| B | −187.1 | −3.0 | |||||
| 6 | DMSO | 2218.8 | 466.5 (21.0%) | 71.7 | A | −168.9 | +4.6 |
| B | −164.3 | +4.5 |
Variation of the unit-cell parameters
Despite the isostructural nature of the solvates, the unit-cell parameters differ quite significantly, with a difference of ca 250 Å3 between the smallest (6) and largest (4) volumes. Plotting the b or c axis of 1–6 by ascending length (see supporting information) shows an approximately linear change in each case, but plotting the a axis in a similar manner shows a clear discontinuity, with the a axis in 4 and 5 being approximately 0.5 Å longer than in 1, 2, 3 and 6. A similar pattern is seen for the β angle, indicating a relative skewing of the ac plane in 4 and 5. Comparing representative structures in projection along the b axis (Fig. 9 ▸) indicates a reason for this observation. Common to structures 4 and 5, but not present in 1, 2, 3 or 6, is an N—CH3 group in the solvent molecule that points approximately along the a axis and is directed towards a neighbouring toluene ring of celecoxib. The interaction pushes the toluene ring away from the position seen in the structures that do not have this N—CH3 group. The celecoxib molecules are ‘anchored’ by their hydrogen-bonding NH2 groups, which retain essentially identical positions in all structures, so the effect of pushing away the toluene ring is a relative rotation of the celecoxib molecules (Fig. 9 ▸). This serves to elongate both the a and the c axes, and to skew the unit cell. The other CH3 groups in TMU (4) or DMPU (5) adopt positions that are seen in one or more of the other structures, and they do not make any clearly comparable intermolecular contacts to celecoxib.
Figure 9.
Projection of the structures of 4 (standard colour) and 6 (green) along the b axis. The highlighted N—CH3⋯π interaction in 4 [C2S⋯centroid(C5–C10) = 3.825 Å] causes the celecoxib molecules to rotate outwards relative to each other, as indicated by the thick arrows, causing expansion and skewing of the unit cell compared to 6.
Interactions between the solvent molecules and celecoxib
On account of the isostructurality, the pairwise intermolecular interactions in each structure can be directly matched. Table 2 ▸ lists the total interaction energy between the celecoxib and solvent molecules, based on an equivalent set of interactions in each structure. For 1–5, the total celecoxib–solvent interaction energy broadly increases with the molecular volume of the solvent, with 2 (DMA) and 3 (NMP) being closely comparable. The DMSO molecule in 6 has a significantly more stabilizing total interaction with celecoxib, compared to the similarly-sized DMF molecule in 1, due to the increased polarity of the S=O bond. For example, the two independent pairwise interactions including the hydrogen bonds to celecoxib are both approximately −50 kJ mol−1 in 1 (varying slightly for the two disorder components), but approximately −57 and −68 kJ mol−1 in 6. The N—CH3⋯π interaction highlighted in Fig. 9 ▸ belongs to the celecoxib–solvent pair within the asymmetric unit (as shown in Figs. 4 ▸ and 5 ▸). Since PIXEL energies refer to total pairwise intermolecular interactions, any specific features of the N—CH3⋯π interaction are masked by the total interaction energy. Table 2 ▸ also lists the total interaction energy between solvent molecules, based on three equivalent significant interactions in each structure. The interaction between the two solvent molecules involved in the hydrogen-bonded motif (Fig. 7 ▸) is repulsive, due to the destabilizing Coulombic O⋯O interaction. The only other significant interactions between solvent molecules are along the 21 screw axis parallel to b, which are slightly stabilizing. The extent to which these interactions mitigate the destabilizing O⋯O interaction increases with the molecular volume of the solvent, and the overall solvent–solvent interaction is slightly stabilizing for the largest molecule, i.e. DMPU (5).
The difference between the total interaction energies with the celecoxib framework for the two disorder components of the solvent molecules in each structure is also shown in Table 2 ▸. The most significant difference within a single structure is seen for DMF (1), where the two orientations exchange the positions of the C—H and N—CH3 groups (Fig. 1 ▸). Approximately two thirds of the energy difference arises from the interactions of the DMF molecule with the two celecoxib molecules in the hydrogen-bonding motif (Fig. 7 ▸), where the more stable DMF orientation brings the CH3 group of atom C2S into close proximity to O1 in one of the S=O bonds (Fig. 10 ▸). For DMA (2), the disorder components have essentially the same molecular footprint (the positions of atoms O1S, C2S, C3S and C4S are common to both DMA components; Fig. 2 ▸), and the total interaction energies of the two components with the celecoxib framework are the same within the expected precision of the calculations. For NMP (3), the two solvent orientations are geometrically comparable, except for the positions of C3S/C3SA (Fig. 3 ▸). However, one orientation is noticeably more stable than the other. A significant energy difference also exists for the two orientations of the DMPU molecule in 5, for which the principal geometrical difference is the position of one CH2 group (C3S/C3SA), with accompanying differences in the positions of the H atoms on the neighbouring CH2 groups. Comparing the most stable disorder components for 3 and 5, they share a common position for one CH2 group (C3S in 3 and C2S in 5) that is not seen in the other disorder components. This introduces a short C—H⋯O contact to an S=O group of the neighbouring celecoxib molecule (Fig. 11 ▸). The PIXEL energies confirm that the interaction with this celecoxib molecule is significantly more stabilizing when this contact is present than when it is not. For the DMSO molecules in 6, the difference between the two solvent orientations involves only the position of the S atom, and the interaction energies with the celecoxib framework are comparable.
Figure 10.
The most stable orientation of the disordered DMF molecule in 1, highlighting the C—H⋯O contact to an S=O group of celecoxib [symmetry code: (i) −x + 1, −y + 1, −z + 1]. The less stable DMF orientation is shown as semi-transparent.
Figure 11.
The most stable orientation of the disordered NMP molecule in 3. A short C—H⋯O contact is made to an S=O group of the neighbouring celecoxib molecule [symmetry code: (ii) x, −y +
, z −
]. The less stable NMP orientation for 3 is shown as semi-transparent. A comparable C—H⋯O contact is seen for the most stable disorder component of DMPU in 5.
Conclusion
This set of six isostructural celecoxib solvates includes small solvent molecules that can accept hydrogen bonds. The host celecoxib framework is consistent within the set, but it shows quite substantial flexibility in its unit-cell parameters and solvent-accessible void space, and can therefore accommodate solvent molecules of varying size and shape. The crystallographic disorder in several of the structures is understandable on the basis of the local twofold symmetry of the solvent binding site, compared to the point symmetry of the solvent molecules. In the absence of any additional hydrogen-bond donors in the solvent molecules, the next most stabilizing interactions between the solvent molecules and the celecoxib framework are C—H⋯O contacts to the S=O groups. The consideration of PIXEL interaction energies, in combination with geometrical analysis of the crystal structures, is helpful in drawing these conclusions.
Supplementary Material
Crystal structure: contains datablock(s) 1, 2, 3, 4, 5, 6, global. DOI: 10.1107/S2053229620008359/sk3751sup1.cif
Structure factors: contains datablock(s) 1. DOI: 10.1107/S2053229620008359/sk37511sup2.hkl
Structure factors: contains datablock(s) 2. DOI: 10.1107/S2053229620008359/sk37512sup3.hkl
Structure factors: contains datablock(s) 3. DOI: 10.1107/S2053229620008359/sk37513sup4.hkl
Structure factors: contains datablock(s) 4. DOI: 10.1107/S2053229620008359/sk37514sup5.hkl
Structure factors: contains datablock(s) 5. DOI: 10.1107/S2053229620008359/sk37515sup6.hkl
Structure factors: contains datablock(s) 6. DOI: 10.1107/S2053229620008359/sk37516sup7.hkl
Unit-cell volume and a/b/c/beta parameter plots. DOI: 10.1107/S2053229620008359/sk3751sup8.pdf
Supporting information file. DOI: 10.1107/S2053229620008359/sk37511sup9.cml
Supporting information file. DOI: 10.1107/S2053229620008359/sk37512sup10.cml
Supporting information file. DOI: 10.1107/S2053229620008359/sk37513sup11.cml
Supporting information file. DOI: 10.1107/S2053229620008359/sk37514sup12.cml
Supporting information file. DOI: 10.1107/S2053229620008359/sk37515sup13.cml
Supporting information file. DOI: 10.1107/S2053229620008359/sk37516sup14.cml
Additional CIFs (DFT calculations). DOI: 10.1107/S2053229620008359/sk3751sup15.txt
Funding Statement
This work was funded by The Lundbeck Foundation (Denmark) grant R143-2014-25. Danish Council for Independent Research | Natural Sciences grant DFF-1323-00122.
References
- Accelrys (2011). Materials Studio. Accelrys Software Inc., San Diego, CA, USA.
- Aitipamula, S., et al. (2012). Cryst. Growth Des. 12, 2147–2152.
- Bolla, G., Mittapalli, S. & Nangia, A. (2014). CrystEngComm, 16, 24–27.
- Bolla, G. & Nangia, A. (2019). IUCrJ, 6, 751–760. [DOI] [PMC free article] [PubMed]
- Bruker (2016). SADABS. Bruker AXS Inc., Madison, Wisconsin, USA.
- Bruker (2018). APEX3 and SAINT. Bruker AXS Inc., Madison, Wisconsin, USA.
- Chawla, G., Gupta, P., Thilagavathi, R., Chakraborti, A. K. & Bansal, A. K. (2003). Eur. J. Pharm. Sci. 20, 305–317. [DOI] [PubMed]
- Chen, H., Paul, S., Xu, H., Wang, K., Mahanthappa, M. K. & Sun, C. C. (2020). Mol. Pharm. 17, 1387–1396. [DOI] [PubMed]
- Clark, S. J., Segall, M. D., Pickard, C. J., Hasnip, P. J., Probert, M. J., Refson, K. & Payne, M. C. (2005). Z. Kristallogr 220, 567–570.
- Dev, R. V., Rekha, K. S., Vyas, K., Mohanti, S. B., Kumar, P. R. & Reddy, G. O. (1999). Acta Cryst C55, 9900161.
- Gavezzotti, A. (2002). J. Phys. Chem. B, 106, 4145–4154.
- Gavezzotti, A. (2003). J. Phys. Chem. B, 107, 2344–2353.
- Gavezzotti, A. (2011). New J. Chem. 35, 1360.
- Grimme, S. (2006). J. Comput. Chem. 27, 1787–1799. [DOI] [PubMed]
- Groom, C. R., Bruno, I. J., Lightfoot, M. P. & Ward, S. C. (2016). Acta Cryst. B72, 171–179. [DOI] [PMC free article] [PubMed]
- Li, D., Kong, M., Li, J., Deng, Z. & Zhang, H. (2018). CrystEngComm, 20, 5112–5118.
- Lu, G. W., Hawley, M., Smith, M., Geiger, B. M. & Pfund, W. (2006). J. Pharm. Sci. 95, 305–317. [DOI] [PubMed]
- Macrae, C. F., Sovago, I., Cottrell, S. J., Galek, P. T. A., McCabe, P., Pidcock, E., Platings, M., Shields, G. P., Stevens, J. S., Towler, M. & Wood, P. A. (2020). J. Appl. Cryst. 53, 226–235. [DOI] [PMC free article] [PubMed]
- Morissette, S. L., Almarsson, O., Peterson, M. L., Remenar, J. F., Read, M. J., Lemmo, A. V., Ellis, S., Cima, M. J. & Gardner, C. R. (2004). Adv. Drug Deliv. Rev. 56, 275–300. [DOI] [PubMed]
- Paul, S., Taylor, L. J., Murphy, B., Krzyzaniak, J., Dawson, N., Mullarney, M. P., Meenan, P. & Sun, C. C. (2017). J. Pharm. Sci. 106, 151–158. [DOI] [PubMed]
- Paul, S., Taylor, L. J., Murphy, B., Krzyzaniak, J. F., Dawson, N., Mullarney, M. P., Meenan, P. & Sun, C. C. (2020). Mol. Pharm. 17, 1148–1158. [DOI] [PubMed]
- Perdew, J. P., Burke, K. & Ernzerhof, M. (1996). Phys. Rev. Lett. 77, 3865–3868. [DOI] [PubMed]
- Sheldrick, G. M. (2015a). Acta Cryst. A71, 3–8.
- Sheldrick, G. M. (2015b). Acta Cryst C71, 3–8.
- Streek, J. van de & Neumann, M. A. (2010). Acta Cryst. B66, 544–558. [DOI] [PMC free article] [PubMed]
- Sun, C. C. (2009). J. Pharm. Sci. 98, 1671–1687. [DOI] [PubMed]
- Wang, C., Paul, S., Sun, D. J., Nilsson Lill, S. O. & Sun, C. C. (2020). Cryst. Growth Des. doi: 10.1021/acs.cgd.0c00492.
- Wang, K., Mishra, M. K. & Sun, C. C. (2019). Chem. Mater. 31, 1794–1799.
- Wang, K. & Sun, C. C. (2019). Cryst. Growth Des. 19, 3592–3600.
- Wang, X., Zhang, Q., Jiang, L., Xu, Y. & Mei, X. (2014). CrystEngComm, 16, 10959–10968.
- Zhang, S.-W., Brunskill, A. P. J., Schwartz, E. & Sun, S. (2017). Cryst. Growth Des. 17, 2836–2843.
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Crystal structure: contains datablock(s) 1, 2, 3, 4, 5, 6, global. DOI: 10.1107/S2053229620008359/sk3751sup1.cif
Structure factors: contains datablock(s) 1. DOI: 10.1107/S2053229620008359/sk37511sup2.hkl
Structure factors: contains datablock(s) 2. DOI: 10.1107/S2053229620008359/sk37512sup3.hkl
Structure factors: contains datablock(s) 3. DOI: 10.1107/S2053229620008359/sk37513sup4.hkl
Structure factors: contains datablock(s) 4. DOI: 10.1107/S2053229620008359/sk37514sup5.hkl
Structure factors: contains datablock(s) 5. DOI: 10.1107/S2053229620008359/sk37515sup6.hkl
Structure factors: contains datablock(s) 6. DOI: 10.1107/S2053229620008359/sk37516sup7.hkl
Unit-cell volume and a/b/c/beta parameter plots. DOI: 10.1107/S2053229620008359/sk3751sup8.pdf
Supporting information file. DOI: 10.1107/S2053229620008359/sk37511sup9.cml
Supporting information file. DOI: 10.1107/S2053229620008359/sk37512sup10.cml
Supporting information file. DOI: 10.1107/S2053229620008359/sk37513sup11.cml
Supporting information file. DOI: 10.1107/S2053229620008359/sk37514sup12.cml
Supporting information file. DOI: 10.1107/S2053229620008359/sk37515sup13.cml
Supporting information file. DOI: 10.1107/S2053229620008359/sk37516sup14.cml
Additional CIFs (DFT calculations). DOI: 10.1107/S2053229620008359/sk3751sup15.txt











